Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14SVV | ISIN: FR0012596468 | Ticker-Symbol: RFM
München
29.07.25 | 08:14
0,360 Euro
+0,84 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSORION SA Chart 1 Jahr
5-Tage-Chart
SENSORION SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3730,38429.07.

Aktuelle News zur SENSORION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSensorion completes enrollment for second cohort in gene therapy trial3
DiSensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial198Regulatory News: Sensorion (FR0012596468 ALSEN),a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
01.07.Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial275SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far Three-month results from a SENS-501 treated toddler in the first...
► Artikel lesen
13.05.Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions350Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
06.05.Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting309Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
25.04.Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting519Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
18.04.Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 12, 2025460Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
SENSORION Aktie jetzt für 0€ handeln
16.04.Sensorion to Host a Symposium during ISIET's International Conference on Inner Ear Therapies on April 26, 2025362Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
02.04.Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director358Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
31.03.Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025296Sensorion to host a webconference dedicated to its retail shareholders on April 7, 2025, in French, at 6.30pm CET (12.30pm ET) Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering...
► Artikel lesen
26.03.Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences599 Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing...
► Artikel lesen
14.03.Sensorion reports FY results4
14.03.Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report16.157Enrolled first cohort into SENS-501's Phase 1/2 clinical trial, Audiogene, and received a positive DMC recommendation; enrollment of second cohort and KOL event to present new data expected during...
► Artikel lesen
07.03.Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity438Regulatory News: Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss...
► Artikel lesen
21.02.Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501's Audiogene Phase 1/2 Clinical Trial370Committee recommends continuation of Audiogene after reviewing first cohort safety data Completion of Audiogene's second cohort enrollment on track for H1 2025 Regulatory News: Sensorion...
► Artikel lesen
20.02.Sensorion Announces Its Participation in Several Investor Conferences to be Held in March403Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing...
► Artikel lesen
18.02.Sensorion Announces Its Participation In Several Congresses To Be Held In March393Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing...
► Artikel lesen
12.02.Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting310Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders...
► Artikel lesen
27.12.24Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial591Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
18.12.24Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial517SENS-501 gene therapy product and surgical procedure are well tolerated by the first two treated patients and encouraging behavioural changes are observed in both toddlers Sensorion plans...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1